Jump to main content
Jump to site search


The feasibility of ROS- and GSH-responsive micelles for treating tumor-initiating and metastatic cancer stem cells

Author affiliations

Abstract

Currently, research on cancer therapy is focused on cancer stem cell therapy to overcome drug resistance and tumor recurrence. Although most studies thereof have focused on the effects of functional nanocarriers on cancer therapy, there is little discussion on the effect of nanocarriers on tumor-initiating cancer stem cells (TICSCs) and metastatic cancer stem cells (MCSCs). Therefore, a glutathione (GSH)-responsive micelle, a reactive oxygen species (ROS)-responsive micelle, and a dual GSH-/ROS-responsive micelle were prepared to evaluate the feasibility of using stimuli-responsive micelles to treat TICSCs and MCSCs. The experimental results demonstrate that ROS-responsive and dual ROS-/GSH-responsive micelles efficiently induce the death of both TICSCs and MCSCs because they could release drugs on both CSCs. However, GSH-responsive micelles were sensitive to TICSCs but not to MCSCs because the latter expressed a low GSH level. Relevant results suggest that the micelles with an ROS-responsive characteristic have great potential for delivering payloads efficiently to treat both TICSCs and MCSCs.

Graphical abstract: The feasibility of ROS- and GSH-responsive micelles for treating tumor-initiating and metastatic cancer stem cells

Back to tab navigation

Supplementary files

Publication details

The article was received on 09 Nov 2018, accepted on 03 Apr 2019 and first published on 03 Apr 2019


Article type: Paper
DOI: 10.1039/C8TB02958J
Citation: J. Mater. Chem. B, 2019, Advance Article

  •   Request permissions

    The feasibility of ROS- and GSH-responsive micelles for treating tumor-initiating and metastatic cancer stem cells

    L. Yu, Y. Shen, M. Chen, Y. Wen, P. Hsieh and C. Lo, J. Mater. Chem. B, 2019, Advance Article , DOI: 10.1039/C8TB02958J

Search articles by author

Spotlight

Advertisements